Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism

Molecular Biology of the Cell

Volumn 15, Issue 11, 2004, Pages 4841-4853

  Pore, Nabendu ^a   Liu, Shuang ^a   Shu, Hui Kuo ^a   Li, Bin ^a   Haas Kogan, Daphne ^b   Stokoe, David ^b   Milanini Mongiat, Julie ^c   Pages, Gilles ^c   O'Rourke, Donald M ^a   Bernhard, Eric ^a   Maity, Amit ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Inst Sign Devmtl Biol/Cancer R   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOVIRIDAE; ALKALINE PHOSPHATASE; ANOXIA; BASE SEQUENCE; BINDING SITES; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; COLLAGEN; DENSITOMETRY; DNA-BINDING PROTEINS; DRUG COMBINATIONS; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LAMININ; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; PHOSPHATES; PHOSPHORYLATION; PLASMIDS; PLICAMYCIN; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 6344275304     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E04-05-0374     Document Type: Article

References (54)

1. Abe, T., Terada, K., Wakimoto, H., Inoue, R., Tyminski, E., Bookstein, R., Basilion, J.P., and Chiocca, E.A. (2003). PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 63, 2300-2305.
2. Arbiser, J.L. et al. (1997). Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94, 861-866.
3. Arsham, A.M., Plas, D.R., Thompson, C.B., and Simon, M.C. (2004). Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 64, 3500-3507.
4. Bergers, G., and Benjamin, L.E. (2003). Angiogenesis: tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.
5. Black, A.R., Black, J.D., and Azizkhan-Clifford, J. (2001). Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188, 143-160.
6. Blume, S.W., Snyder, R.C., Ray, R., Thomas, S., Koller, C.A., and Miller, D.M. (1991). Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 88, 1613-1621.
7. Bogler, O., and Mikkelsen, T. (2003). Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J. 9, 205-213.
8. Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R., and Kaelin, W.G., Jr. (2003). TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158.
9. Cantley, L.C., and Neel, B.C. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 96, 4240-4245.
10. Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. (1983). Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11, 1475-1489.
11. El-Hashemite, N., Walker, V., Zhang, H., and Kwiatkowski, DJ. (2003). Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63, 5173-5177.
12. Feldkamp, M.M., Lau, N., Rak, J., Kerbel, R.S., and Guha, A. (1999). Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81, 118-124.
13. Ferrara, N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14.
14. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D., and Siemeister, G. (1997). Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 15, 669-676.
15. Forsythe, J.A., Jiang, B.H., Iyer, N.V., Agani, F., Leung, S.W., Koos, R.D., and Semenza, G.L. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613.
16. Gille, J., Khalik, M., Konig, V., and Kaufmann, R. (1998). Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J. Invest. Dermatol. 111, 1160-1165.
17. Gille, J., Swerlick, R.A., and Caughman, S.W. (1997). Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16, 750-759.
18. Gomez-Manzano, C. et al. (2003). Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann. Neurol. 53, 109-117.
19. Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., and Stokoe, D. (1998). Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8, 1195-1198.
20. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and Weinberg, R.A. (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468.
21. He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509-2514.
22. Jiang, B.H., Zheng, J.Z., Aoki, M., and Vogt, P.K. (2000). Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA 97, 1749-1753.
23. Juarez, J.C. et al. (2002). Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 62, 5344-5350.
24. Knobbe, C.B., Merlo, A., and Reifenberger, G. (2002). Pten signaling in gliomas. Neuro-oncology 4, 196-211.
25. Koul, D., Shen, R., Garyali, A., Ke, L.D., Liu, T.J., and Yung, W.K. (2002). MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int. J. Oncol. 21, 469-475.
26. Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C., and Semenza, G.L. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004.
27. Maity, A., Pore, N., Lee, J., Solomon, D., and O'Rourke, D.M. (2000). Epidermal growth factor receptor (EGFR) transcriptionally upregulates VEGF expression in human glioblastoma cells via a pathway involving PI(3) kinase and distinct from that induced by hypoxia. Cancer Res. 60, 5879-5886.
28. Manley, P.W., Martiny-Baron, G., Schlaeppi, J.M., and Wood, J.M. (2002). Therapies directed at vascular endothelial growth factor. Expert Opin. Investig. Drugs 11, 1715-1736.
29. Mazure, N.M., Chen, E.Y., Laderoute, K.R., and Giaccia, AJ. (1997). Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90, 3322-3331.
30. Mazure, N.M., Chen, E.Y., Yeh, P., Laderoute, K.R., and Giaccia, AJ. (1996). Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56, 3436-3440.
31. Milanini, J., Vinals, F., Pouyssegur, J., and Pages, G. (1998). p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273, 18165-18172.
32. Milanini-Mongiat, J., Pouyssegur, J., and Pages, G. (2002). Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277, 20631-20639.
33. Nehls, M.C., Brenner, D.A., Gruss, HJ., Dierbach, H., Mertelsmann, R., and Herrmann, F. (1993). Mithramycin selectively inhibits collagen-alpha 1(1) gene expression in human fibroblast. J. Clin. Invest. 92, 2916-2921.
34. Paez, J., and Sellers, W.R. (2003). PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. 115, 145-167.
35. Pore, N., Liu, S., Haas-Kogan, D.A., O'Rourke, D.M., and Maity, A. (2003). PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res. 63, 236-241.
36. Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., Mansour, S.J., Ahn, N.G., and Kerbel, R.S. (2000). Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60, 490-498.
37. Rak, J., Yu, J.L., Kerbel, R.S., and Coomber, B.L. (2002). What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62, 1931-1934.
38. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H.A., Kohno, K., and Kuwano, M. (1996). Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271, 28220-28228.
39. Schafer, G., Cramer, T., Suske, G., Kemmner, W., Wiedenmann, B., and Hocker, M. (2003). Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem. 278, 8190-8198.
40. Sen, C.K., Khanna, S., Babior, B.M., Hunt, T.K., Ellison, E.G., and Roy, S. (2002). Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing. J. Biol. Chem. 277, 33284-33290.
41. Shi, Q. et al. (2001). Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 62, 4143-4154.
42. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
43. Testa, J.R., and Bellacosa, A. (2001). AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 10983-10985.
44. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L., and Van Obberghen, E. (2002). Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975-27981.
45. Udvadia, A.J., Rogers, K.T., Higgins, P.D., Murata, Y., Martin, K.H., Humphrey, P.A., and Horowitz, J.M. (1993). Sp-1 binds promoter elements regulated by the RB protein and Sp-1-mediated transcription is stimulated by RB coexpression. Proc. Natl. Acad. Sci. USA 90, 3265-3269.
46. Udvadia, AJ., Templeton, DJ., and Horowitz, J.M. (1995). Functional interactions between the retinoblastoma (Rb) protein and Sp-family members: superactivation by Rb requires amino acids necessary for growth suppression. Proc. Natl. Acad. Sci. USA 92, 3953-3957.
47. Vivanco, I., and Sawyers, CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
48. Wankhade, S., Yu, Y., Weinberg, J., Tainsky, M.A., and Kannan, P. (2000). Characterization of the activation domains of AP-2 family transcription factors. J. Biol. Chem. 275, 29701-29708.
49. Wen, S., Stolarov, J., Myers, M.P., Su, J.D., Wigler, M.H., Tonks, N.K., and Durden, D.L. (2001). PTEN controls tumor-induced angiogenesis. Proc. Natl. Acad. Sci. USA 98, 4622-4627.
50. Woods, S.A., McGlade, C.J., and Guha, A. (2002). Phosphatidylinositol 3′-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells. Neuro-oncology 4, 242-252.
51. Wu, X., Senechal, K., Neshat, M.S., Whang, Y.E., and Sawyers, C.L. (1998). The PTEN/MMAC1 rumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 95, 15587-15591.
52. Yamada, K.M., and Araki, M. (2001). Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 114, 2375-2382.
53. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.M., Simons, J.W., and Semenza, G.L. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545.
54. Zundel, W. et al. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396.